Search
170 studies match these filters. Showing 76–100 of 170 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT07830719 | Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and residual inflammatory risk defined by eleva… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 23 sites in total · contact listed | Recruiting | Phase 2 | 180target | 23 / 5 | 2026 | Oct 15, 2026 | |
| NCT07578116 | Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis This phase III trial evaluates the effect of adding locoregional therapy (surgery and radiation) and metastasis-directed stereotactic body radiation therapy (SBRT) to standard systemic therapy following standard HER2-targeted systemic therapy, compared to standard systemic therapy alone, in treating… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 59 sites in total · contact listed | Recruiting | Phase 3 | 562target | 59 / 1 | 2027 | Oct 13, 2026 | |
| NCT07667803 | A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exerci… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 325 sites in total | Recruiting | Phase 3 | 4,500target | 325 / 19 | 2026 | Oct 13, 2026 | |
| NCT07206056 | An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 35 sites in total · contact listed | Recruiting | Phase 1 / Phase 2 | 188target | 35 / 14 | 2025 | Oct 9, 2026 | |
| NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasi… ✓ Contact✗ Claimed Nearest site: El Dorado, Kansas, United States — 85 km away · 563 sites in total · contact listed | Recruiting | Phase 3 | 4,500target | 563 / 34 | 2025 | Oct 8, 2026 | |
| NCT07296484 | Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 61 sites in total · contact listed | Recruiting | Phase 2 | 1,500target | 61 / 1 | 2025 | Oct 6, 2026 | |
| NCT06237452 | VE303 for Prevention of Recurrent Clostridioides Difficile Infection The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 215 sites in total | Recruiting | Phase 3 | 852target | 215 / 24 | 2024 | Nov 13, 2026 | |
| NCT04181060 | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signa… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 604 sites in total · contact listed | Recruiting | Phase 3 | 300target | 604 / 1 | 2020 | Nov 4, 2026 | |
| NCT07570316 | A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody l… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 35 sites in total · contact listed | Recruiting | Phase 3 | 230target | 35 / 3 | 2026 | Nov 3, 2026 | |
| NCT07684144 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION) The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 45 sites in total | Recruiting | Phase 3 | 950target | 45 / 5 | 2026 | Oct 5, 2026 | |
| NCT07684235 | Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION) The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839). ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 92 sites in total | Recruiting | Phase 3 | 3,200target | 92 / 5 | 2026 | Oct 5, 2026 | |
| NCT06283966 | A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 922 sites in total | Recruiting | Phase 3 | 5,250target | 922 / 37 | 2024 | Oct 2, 2026 | |
| NCT06876714 | ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherap… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 702 sites in total · contact listed | Recruiting | Phase 3 | 1,524target | 702 / 2 | 2025 | Oct 2, 2026 | |
| NCT07564414 | A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eith… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 303 sites in total | Recruiting | Phase 3 | 2,500target | 303 / 19 | 2026 | Sep 30, 2026 | |
| NCT05102019 | Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II To demonstrate the safety and effectiveness of the Shockwave Reducer for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coro… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 97 sites in total | Recruiting | Not applicable | 380target | 97 / 3 | 2022 | Sep 30, 2026 | |
| NCT07817251 | Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months. ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 40 sites in total | Recruiting | Phase 3 | 210target | 40 / 1 | 2026 | Sep 30, 2026 | |
| NCT07624305 | A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a p… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 478 sites in total | Recruiting | Phase 3 | 2,800target | 478 / 27 | 2026 | Sep 24, 2026 | |
| NCT06605404 | Pan-tumor MRD Study The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, fo… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 47 sites in total · contact listed | Recruiting | 1,350target | 47 / 1 | 2025 | Sep 24, 2026 | ||
| NCT06777368 | REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR). ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 71 sites in total · contact listed | Recruiting | 225target | 71 / 1 | 2025 | Sep 24, 2026 | ||
| NCT07326709 | A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm. HTT227 - current compound code (former code is PTC518 from PTC Therapeutics), HTT227 is… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 117 sites in total · contact listed | Recruiting | Phase 3 | 770target | 117 / 27 | 2026 | Sep 22, 2026 | |
| NCT06990867 | Optimizing Reperfusion to Improve Outcomes and Neurologic Function The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 104 sites in total · contact listed | Recruiting | Phase 2 / Phase 3 | 740target | 104 / 21 | 2025 | Sep 21, 2026 | |
| NCT05485961 | Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo. Part 2: Phase 3 aims to assess the efficacy of CSL300 vs placebo on cardiovascular (CV) out… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 566 sites in total · contact listed | Recruiting | Phase 2 / Phase 3 | 3,110target | 566 / 35 | 2024 | Sep 21, 2026 | |
| NCT06423911 | Study of Olverembatinib (HQP1351) in Patients With CML-CP Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T315I mutation (Part B). Patients who meet ELN 2025 failure c… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 163 sites in total | Recruiting | Phase 3 | 333target | 163 / 16 | 2024 | Sep 15, 2026 | |
| NCT07779408 | Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above. The study aims to evaluate an egg-based H5N8 influenza vaccine up to 3 dose levels (low, medium, and high dose) given with or without adjuvant to see if the adjuvant improves vaccine effectiveness. The study will enroll healthy adults aged 18 years and over. Participants will receive 2 injections i… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 16 sites in total | Recruiting | Phase 1 / Phase 2 | 640target | 16 / 1 | 2026 | Sep 15, 2026 | |
| NCT06033274 | Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment The field of transcatheter tricuspid valve replacement (TTVR) is rapidly emerging and data on this topic are scarce. Particularly, little is known about which patients are at greatest risk of procedural complications, such as the timing and onset of conduction disturbances necessitating permanent pa… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 31 sites in total | Recruiting | 800target | 31 / 8 | 2023 | Sep 15, 2026 |